Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;18(3):161-168.
doi: 10.1016/S1875-5364(20)30017-0.

Fatty liver diseases, mechanisms, and potential therapeutic plant medicines

Affiliations
Review

Fatty liver diseases, mechanisms, and potential therapeutic plant medicines

Jia-Zhen Zhu et al. Chin J Nat Med. 2020 Mar.

Abstract

The liver is an important metabolic organ and controls lipid, glucose and energy metabolism. Dysruption of hepatic lipid metabolism is often associated with fatty liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver diseases (AFLD) and hyperlipidemia. Recent studies have uncovered the contribution of hormones, transcription factors, and inflammatory cytokines to the pathogenesis of dyslipidemia and fatty liver diseases. Moreover, a significant amount of effort has been put to examine the mechanisms underlying the potential therapeutic effects of many natural plant products on fatty liver diseases and metabolic diseases. We review the current understanding of insulin, thyroid hormone and inflammatory cytokines in regulating hepatic lipid metabolism, focusing on several essential transcription regulators, such as Sirtuins (SIRTs), Forkhead box O (FoxO), Sterol-regulatory element-binding proteins (SREBPs). We also discuss a few representative natural products with promising thereapeutic effects on fatty liver disease and dyslipidemia.

Keywords: Fatty liver disease; Hormones; Inflammatory cytokines; Lipid metabolism; Natural products; Transcription factors.

PubMed Disclaimer

Conflict of interest statement

These authors have no conflict of interest to declare.

Similar articles

Cited by

References

    1. Scaglioni F, Ciccia S, Marino M, et al. ASH and NASH [J]. Dig Dis, 2011, 29(2): 202–210. - PubMed
    1. Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease [J]. Gastroenterology, 2020: S0016–5085(0020)30171–30172 [Epub ahead of print]. - PubMed
    1. Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis [J]. Hepatology, 2019, 70(4): 1119–1133. - PubMed
    1. Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population [J]. World journal of gastroenterol, 2014, 20(47): 17932–17940. - PMC - PubMed
    1. Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver disease and the economy in China: a systematic review [J]. World J Gastroenterol, 2015, 21(18): 5695–5706. - PMC - PubMed